Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT1718 in advanced solid tumours
ISRCTN11160449Phase 2Completed
- Sponsor
- Cancer Research UK
- Start
- Jan 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
01
Overview
Phase 2, open-label trial of BT1718 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and esophageal cancer (5 arms), sponsored by Cancer Research UK. Primary endpoints: Maximum tolerated or recommended dose based on dose-limiting toxicity and Safety and tolerability. Started Jan 2018; status: completed.
02
Drugs
BT1718
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on ISRCTN11160449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11160449.